ATG16L2 and cervical carcinoma: Consistent with our hypothesis, ZBTB28 could directly activate the FIP200 and ATG16L2 wild-type promoter activities in 293 T and cervical cancer cells, however it was incapable of activating the promoters of mutant one (Fig. 7d, e, Fig. S3E).